Data_Sheet_1_Thrombotic Events in COVID-19 Are Associated With a Lower Use of Prophylactic Anticoagulation Before Hospitalization and Followed by Decreases in Platelet Reactivity.d... by Chantal C. Clark (10684632)

Differences in abundance of non-lipid molecules in liver of <i>Fmo5</i>^<i>-/-</i> and WT mice. by Ian R. Phillips (5074121)

“…<p>(A) Volcano plot representation of non-lipid molecules (log₂-fold change) of <i>Fmo5</i>^<i>-/-</i> vs WT mice. …”

Evidence of decreased system justification among extreme conservatives in non-American samples by Luca Caricati (6259799)

DataSheet_1_Effects of immunophilin inhibitors and non-immunosuppressive analogs on coronavirus replication in human infection models.pdf by Emilia J. Berthold (13839388)

“…</p>Results<p>Both CsA and ALV robustly inhibited viral replication in all models; both compounds decreased HCoV-229E RNA in phBECs and reduced luminescence in HCoV-229E-RLuc-infected Huh7.5 and SARS-CoV-1-RLuc replicon-transfected HEK293. …”

Month set comparisons. by Nicole R. Cannarozzi (7901057)

Difference in pathogen detection in children that recently received non-study antibiotics. by Godfrey Guga (12152390)

Inhibition of VEGF-A gene synthesis decreased ranibizumab and aflibercept mediated CCL2 CCL5, and CX3CL1 mRNA and protein levels in HCAECs. by Clare Arnott (2557705)

Decrease of C/EBPβ protein expression attenuates DEX-induced repression of CBG mRNA and protein levels and reduces GR recruitment to the mouse <i>Cbg</i> promoter. by Nicolette Verhoog (647814)

“…Occupancy of GR protein on the endogenous mouse <i>Cbg</i> promoter was detected using primers encompassing the regions defined as P5 to P1. Co-immunoprecipitated DNA fragments and input DNA were analyzed by qPCR and results shown are normalized to a non-specific region within the m<i>Cbg</i> promoter as well as input and expressed relative to NSC vehicle control (0.1% EtOH), which was set as 1. …”

Overexpression of human PGRN mRNA prevents the decrease in axon outgrowth produced by knockdown of zebrafish PGRN. by Angela S. Laird (360986)

“…<p>A) The decreased axonal length produced by knockdown of <i>grna</i> with a 5′UTR MO was rescued by co-expression of PGRN mRNA. * significantly different from grna CO MO, p<0.02; ̂ significantly different from <i>grna</i> MO + GFP, p<0.0001. …”

The decrease of DDB2 proteo-probe and 6-4 PP signals over time are nearly identical. by Matija Dreze (515840)

“…(<b>B</b>) The DDB2 proteo-probe signal decreases exponentially with time. Average signal per nucleus normalized to signal at 5 minutes. …”

Decreased echinocandin susceptibility in <i>Candida parapsilosis</i> causing candidemia and emergence of a pan-echinocandin resistant case in China by Yating Ning (11264310)

Relationship of blood glucose (BG) decrease after insulin IP (15 u/kg) to seizure and survival. by Margaret Maheandiran (503654)

BMP type I receptor antagonists decrease Smad 1/5/8 activity in H1299 cells. by Elaine Langenfeld (402034)

Decreased BK responsiveness of ERK activation is found only in PS-1 FAD mutant AD fibroblasts. by Graziella Mendonsa (374346)

The expression of <i>Wnt1</i> gene was decreased in <i>Bmpr</i> double knockout mutants. by Lihua Qin (494786)

Blockade of TRPV4 inhibited the proliferation and decreased α-SMA expression in activated HSC-T6 cells. by Yang Song (88132)

Down-regulation of GPER reverses the decreased expression of PCNA and cell morphology changes caused by G-1. by Fen Li (337013)

Folding and stability of GDAP1 as affected by CMT mutations. by Aleksi Sutinen (10039145)

Subjects:

<i>RTTN</i>-mutated organoids exhibit decreased proliferation and increased cell death at early stages. by Justine Guguin (9088672)

Subgroup analyses of the association between decreases in serum UA levels and poor functional outcome at 3 months. by Kuniyuki Nakamura (13040299)

“…<p>The ORs and 95% CIs of poor functional outcome (defined as an mRS score of 3–6 at 3 months) are shown according to UA decrease rate grade (G1 to G4) in each subgroup. The subgroups included (<b>A</b>) age (<75 or ≥75 years), (<b>B</b>) sex (women or men), (<b>C</b>) stroke subtype (non-cardioembolic or cardioembolic), (<b>D</b>) neurological severity (NIHSS <5 or ≥5), (<b>E</b>) CKD (presence or absence), and (<b>F</b>) UA level on admission (<292 or ≥292 μmol/L for women, <351 or ≥351 μmol/L for men). …”